If SMA patients who were administering Biogen's Spinraza want to be replaced with Zolgensma, an ultra-high-priced one-shot treatment from Novartis Korea, they should have a minimum administration interval of 4 weeks.

Regardless of whether or not benefit of Zolgensma is applied, replacement administration to other treatments after Zolgensma administration does not recognize the application of benefits. On the 4th, the HIRA guided "Questions and Answers on Zolgensma benefit standards."

Zolgensma will be reimbursed from the 1st of this month as the insurance drug price of 1,981,726,933 won per kit was set through the Health Insurance Policy Review Committee on July 20. It is recommended to h